Clinical trial
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell…
NCT00303953 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00303953 |
|---|---|
| Title | PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma |
| Official title | Phase II Study of PXD101 (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma |
| Intervention type | Drug |
| Interventions | belinostat |
| Enrollment | 22 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Mar 17, 2006 |
| Last update posted | May 12, 2014 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: